Skye Bioscience, Inc. (SKYE)

Name: Skye Bioscience, Inc. (SKYE) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Skye Bioscience, Inc. (SKYE)

Stock Card

$1.78

$-0.18 (-8.97%)

As on 28-Aug-2026 16:13EDT

Market cap

$8 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Skye Bioscience, Inc. (SKYE) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.76 High: 1.95

52 Week Range

Low: 1.76 High: 39.92

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-2.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-2.6
Debt to Equity

0
Book Value

$-0.1
EPS

$-10.2
Face value

--
Shares outstanding

4,427,676

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Skye Bioscience, Inc. (SKYE)	-70.4	-64.4	-73.2	-93.6	151.2	9.6	-8.4
BSE Sensex^*	-9.3	-1.4	2.7	-3.7	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024
Skye Bioscience, Inc. (SKYE)	-73.5	4.0
S&P Small-Cap 600	4.0	7.0
BSE Sensex	9.1	8.1

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Skye Bioscience, Inc. (SKYE)	1.8	7.9	0.0	-50.5	--	--	--	2.0
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	247.9	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Skye Bioscience, Inc. (SKYE)

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a... peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California. Read more

Executive Chairman, President, CEO & Secretary

Mr. Punit S. Dhillon B.A.
President, CEO, Secretary & Director

Mr. Punit S. Dhillon B.A.
Headquarters

San Diego, CA
Website

https://skyebioscience.com

FAQs for Skye Bioscience, Inc. (SKYE)

What is the current share price of Skye Bioscience, Inc (SKYE) Today?

The share price of Skye Bioscience, Inc (SKYE) is $1.78 (NASDAQ) as of 28-Aug-2026 16:13 EDT. Skye Bioscience, Inc (SKYE) has given a return of 151.18% in the last 3 years.

What is the current PB & PE ratio of Skye Bioscience, Inc (SKYE)?

Since, TTM earnings of Skye Bioscience, Inc (SKYE) is negative, P/E ratio is not available.
The P/B ratio of Skye Bioscience, Inc (SKYE) is 1.96 times as on 28-Aug-2026, a 62 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-0.07	0.19
2024	-4.26	1.66
2023	-0.89	-15.76
2022	-0.80	-5.17
2021	-0.01	0.01

What is the 52 Week High and Low of Skye Bioscience, Inc (SKYE)?

The 52-week high and low of Skye Bioscience, Inc (SKYE) are Rs 39.92 and Rs 1.76 as of 31-Aug-2026.

What is the market cap of Skye Bioscience, Inc (SKYE)?

Skye Bioscience, Inc (SKYE) has a market capitalisation of $ 8 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Skye Bioscience, Inc (SKYE)?

Before investing in Skye Bioscience, Inc (SKYE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.